Progressive Pulmonary Fibrosis Pipeline Analysis Report 2026

Report Coverage

The Progressive Pulmonary Fibrosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into progressive pulmonary fibrosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for progressive pulmonary fibrosis. The progressive pulmonary fibrosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The progressive pulmonary fibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with progressive pulmonary fibrosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to progressive pulmonary fibrosis.

Read more about this report - Request a Free Sample

Progressive Pulmonary Fibrosis Pipeline Outlook

Progressive pulmonary fibrosis is a chronic lung disorder characterized by continuous scarring of lung tissue, leading to a gradual decline in respiratory function. It develops as a complication of various interstitial lung diseases, including autoimmune conditions and environmental exposures. Persistent inflammation triggers fibrosis, reducing oxygen transfer and causing worsening breathlessness over time.

Progressive pulmonary fibrosis treatment is done through antifibrotic therapies, immunomodulators, supportive oxygen therapy, pulmonary rehabilitation, and treatment of underlying interstitial lung diseases to slow lung function decline and improve quality of life. In December 2025, Boehringer Ingelheim received U.S. Food and Drug Administration approval for JASCAYD (nerandomilast), a preferential phosphodiesterase 4B inhibitor, for progressive pulmonary fibrosis. The drug demonstrated significant slowing of lung function decline in Phase III clinical trials, marking a major advancement in the disease treatment pipeline.

Progressive Pulmonary Fibrosis Epidemiology

The global incidence of idiopathic pulmonary fibrosis (IPF) is estimated at approximately 10 cases per 100,000 people annually, though rates vary across regions, according to Rare Disease Advisor. In the United States, a 2011 study of Medicare beneficiaries aged 65 years and older reported an incidence of 93.7 cases per 100,000 people and a prevalence of 494.5 cases per 100,000 people. As per Huajian Liu et al., 2024, real-world data from the United Kingdom indicate a higher prevalence of progressive pulmonary fibrosis than previously estimated, with up to 20% of patients starting nintedanib presenting with advanced disease. According to Maria S. Nashatyreva et al., 2023, the overall proportion of IPF was 13.7% in India and 11.6% in the greater Paris region. These findings highlight the growing recognition and burden of progressive pulmonary fibrosis globally.

Progressive Pulmonary Fibrosis – Pipeline Therapeutic Assessment

Progressive Pulmonary Fibrosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 47%, covers a major share of the total progressive pulmonary fibrosis clinical trials, highlighting strong midstage activity and promising therapeutic candidates. Phase III accounts for 33%, indicating significant late‑stage progression and potential near‑term market approvals. Phase I contributes 13%, reflecting early clinical exploration, while phase IV holds 7%, demonstrating post‑marketing evaluation. Together, these phases underscore a balanced and advancing pipeline that can drive innovation, expand treatment options, and positively impact market growth.

Progressive Pulmonary Fibrosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the progressive pulmonary fibrosis pipeline analysis include small molecules, monoclonal antibodies, recombinant proteins, and cell therapies. The progressive pulmonary fibrosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for progressive pulmonary fibrosis. In the pipeline, phosphodiesterase 4B (PDE4B) inhibitors are emerging as promising therapeutic options. For instance, nerandomilast, an oral preferential PDE4B inhibitor, is under investigation in Phase III trials for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. It works by reducing inflammation and slowing lung function decline, demonstrating a favorable safety and tolerability profile compared to placebo.

Progressive Pulmonary Fibrosis Clinical Trials – Key Players

The EMR report for the progressive pulmonary fibrosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed progressive pulmonary fibrosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in progressive pulmonary fibrosis clinical trials:

• Bristol-Myers Squibb
• Avalyn Pharma Inc.
• Sunshine Lake Pharma Co., Ltd.
• Boehringer Ingelheim
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• United Therapeutics
• Endeavor Biomedicines, Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Novartis
• Contineum Therapeutics

Progressive Pulmonary Fibrosis – Emerging Drugs Profile

Key Questions Answered in the Progressive Pulmonary Fibrosis Pipeline Insight Report

• Which companies/institutions are leading progressive pulmonary fibrosis drug development?
• Which company is leading the progressive pulmonary fibrosis pipeline development activities?
• What is the current progressive pulmonary fibrosis commercial assessment?
• What are the opportunities and challenges present in the progressive pulmonary fibrosis pipeline landscape?
• What is the efficacy and safety profile of progressive pulmonary fibrosis pipeline drugs?
• Which company is conducting major trials for progressive pulmonary fibrosis drugs?
• Which companies/institutions are involved in progressive pulmonary fibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in progressive pulmonary fibrosis?

Reasons To Buy This Report

The Progressive Pulmonary Fibrosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for progressive pulmonary fibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into progressive pulmonary fibrosis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Progressive Pulmonary Fibrosis Epidemiology Forecast

Idiopathic Pulmonary Fibrosis Treatment Market